International Journal of Head and Neck Surgery

Register      Login

VOLUME 14 , ISSUE 2 ( April-June, 2023 ) > List of Articles


A Systemic Review on Similarities between Salivary and Mammary Gland Neoplasms and the Role of Antihormonal Therapy in Salivary Gland Tumors

Veena B Ganga, Krishnappa Ramachandrappa, Karthik Shamanna

Keywords : Acinic cell carcinoma, Adenoid cystic carcinoma, Androgen receptor, Epidermal growth factor receptor, Estrogen receptor, Mucoepidermoid carcinoma, Progesterone receptor, Salivary duct carcinoma

Citation Information : Ganga VB, Ramachandrappa K, Shamanna K. A Systemic Review on Similarities between Salivary and Mammary Gland Neoplasms and the Role of Antihormonal Therapy in Salivary Gland Tumors. Int J Head Neck Surg 2023; 14 (2):21-32.

DOI: 10.5005/jp-journals-10001-1549

License: CC BY-NC 4.0

Published Online: 15-06-2023

Copyright Statement:  Copyright © 2023; The Author(s).


Objective: The present review focuses on the morphological, pathological, and molecular level resemblance of salivary and mammary gland neoplasms with emphasis on the current status of hormonal therapy strategies in salivary gland tumors. Methods: Literature review developed in compliance with Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines and data collected from PubMed, Cochrane, Wiley library, and other related reference articles. Results: The expression of hormonal receptors was found to be demonstrated frequently in salivary duct carcinoma, followed by a few other malignant tumors like carcinoma ex pleomorphic adenoma (PA), adenocarcinoma not otherwise specified (NOS) and mucoepidermoid carcinoma (MEC). Conclusion: The similarities in the morphology, biology, and molecular changes between the salivary gland and breast tumors form the basis for the detection of hormonal receptors and the use of antihormonal therapies. The novel treatment strategies of antihuman epidermal growth factor receptor 2 (anti-HER2) and anti-androgen receptor (AR) are currently found to be effective in unresectable/rapidly progressive tumors and in multiple tumor recurrence cases for a few salivary gland tumor histologies.

  1. Sangeetha P, Anitha N, Rajesh E, et al. Embryology and development of salivary gland. Eur J Mol Clin Med 2020;7(10):764–770.
  2. Tucker Tucker AS, Miletich I (eds): Salivary Glands. Development, Adaptations, and Disease. Front Oral Biol Basel, Karger, 2010;14:1–20.
  3. Macias H, Hinck L. Mammary gland development. Wiley Interdiscip Rev Dev Biol 2012;1(4):533–557. DOI: 10.1002/wdev.35
  4. Lewis AG, Tong T, Maghami E. Diagnosis and management of malignant salivary gland tumors of the parotid gland. Otolaryngol Clin North Am 2016;49(2):343–380. DOI: 10.1016/j.otc.2015.11.001
  5. Kratochwil K. Organ specificity in mesenchymal induction demonstrated in the embryonic development of the mammary gland of the mouse. Dev Biol 1969;20(1):46–71. DOI: 10.1016/0012-1606(69)90004-9
  6. Namboodiripad PC. A review: immunological markers for malignant salivary gland tumors. J Oral Biol Craniofac Res 2014;4(2):127–134. DOI: 10.1016/j.jobcr.2014.05.003
  7. Aydogan A, Metin N. Detection of cell origin by immunohistochemistry in canine mammary tumours. Revue Med Vet 2013;164:395–399.
  8. Liu H. Application of immunohistochemistry in breast pathology. Arch Pathol Lab Med 2014;138(12):1629–1642. DOI: 10.5858/arpa.2014-0094-RA
  9. Dwivedi N, Agarwal A, Raj V, et al. Histogenesis of salivary gland neoplasms. Indian J Cancer 2013;50(4):361–366. DOI: 10.4103/0019-509X.123629
  10. Rao RS, Patil S, Amrutha N, et al. The ambiguous salivary myoepithelial cells. J Contemp Dent Pract 2014;15(4):523–528. DOI: 10.5005/jp-journals-10024-1573
  11. Triantafyllou A, Hunt JL, Devaney KO, et al. A perspective of comparative salivary and breast pathology. Part I: microstructural aspects, adaptations and cellular events. Eur Arch Otorhinolaryngol 2014;271(4):647–663. DOI: 10.1007/s00405-013-2488-y
  12. Gudjonsson T, Adriance MC, Sternlicht MD, et al. Myoepithelial cells: their origin and function in breast morphogenesis and neoplasia. J Mammary Gland Biol Neoplasia 2005;10(3):261–272. DOI: 10.1007/s10911-005-9586-4
  13. Boecker W, Stenman G, Loening T, et al. K5/K14-positive cells contribute to salivary gland-like breast tumors with myoepithelial differentiation. Mod Pathol 2013;26(8):1086–1100. DOI: 10.1038/modpathol.2013.45
  14. Foschini MP, Morandi L, Asioli S, et al. The morphological spectrum of salivary gland type tumours of the breast. Pathology 2017;49(2):215–227. DOI: 10.1016/j.pathol.2016.10.011
  15. Davud B Sirjani, James S Lewis, Beth M Beadle, et al. Malignant neoplasms of the salivary glands, chapter85, Cummings otolaryngology and head and neck surgery, 7th edition, volume 2, Kennedy JK, Philadelphia, 2021. pp. 1189–1212.
  16. Larbcharoensub N, Cert PK, Tungkeeratichai J, et al. Expression of hormonal receptor in patients with metastasizing pleomorphic adenoma of the major salivary gland; a clinicopathological report of three cases. J Med Assoc Thai 2009;92(9):1250–1255.
  17. Glas AS, Hollema H, Nap RE, et al. Expression of estrogen receptor, progesterone receptor, and insulin-like growth factor receptor-1 and of MIB-1 in patients with recurrent pleomorphic adenoma of the parotid gland. Cancer 2002;94(8):2211–2216. DOI: 10.1002/cncr.10445
  18. De Souz AA, Altemani A, de Araujo NS, et al. Estrogen receptor, progesterone receptor, and her-2 expression in recurrent pleomorphic adenoma. Clin Pathol 2019;12:2632010X19873384. DOI: 10.1177/2632010X19873384
  19. Di Palma S, Skálová A, Vanìèek T, et al. Non-invasive (intracapsular) carcinoma ex pleomorphic adenoma: recognition of focal carcinoma by HER-2/neu and MIB1 immunohistochemistry. Histopathology 2005;46(2):144–152. DOI: 10.1111/j.1365-2559.2005.02058.x
  20. Di Palma S. Carcinoma ex pleomorphic adenoma, with particular emphasis on early lesions. Head Neck Pathol 2013;7(Suppl 1):S68–S76. DOI: 10.1007/s12105-013-0454-z
  21. Moriki T, Ueta S, Takahashi T, et al. Salivary duct carcinoma: cytologic characteristics and application of androgen receptor immunostaining for diagnosis. Cancer 2001;93(5):344–350. DOI: 10.1002/cncr.9050
  22. Nasser MD, Faquin WC, Dayal Y, et al. Expression of androgen, estrogen, and progesterone receptors in salivary gland tumors. Frequent expression of androgen receptor in a subset of malignant salivary gland tumors. Am J Clin Pathol 2003;119(6):801–806. DOI: 10.1309/RVTP-1G0Q-727W-JUQD
  23. Wong MH, Dobbins TA, Tseung J, et al. Oestrogen receptor beta expression in pleomorphic adenomas of the parotid gland. J Clin Pathol 2009;62(9):789–793. DOI: 10.1136/jcp.2009.065102
  24. Ito FA, Ito K, Coletta RD. Immunohistochemical study of androgen, estrogen and progesterone receptors in salivary gland tumors. Braz Oral Res 2009:23(4):393–398. DOI: 10.1590/s1806-83242009000400008
  25. Nakajima Y, Kishimoto T, Nagai Y, et al. Expressions of androgen receptor and its co-regulators in carcinoma ex pleomorphic adenoma of salivary gland. Pathology 41(7):634–639. DOI: 10.3109/00313020903071595
  26. Can NT, Lingen MW, Mashek H, et al. Expression of hormone receptors and HER-2 in benign and malignant salivary gland tumors. Head Neck Pathol 2017;12(1):95–104. DOI: 10.1007/s12105-017-0833-y
  27. Aquino G, Collina F, Sabatino R, et al. Sex hormone receptors in benign and malignant salivary gland tumors: prognostic and predictive role. Int J Mol Sci 2018;19(2):399. DOI: 10.3390/ijms19020399
  28. Weiler C, Zengel P, van derWal JE, et al. Carcinoma ex pleomorphic adenoma with special reference to the prognostic significance of histological progression: a clinicopathological investigation of 41 cases. Histopathology 2011;59(4):741–750. DOI: 10.1111/j.1365-2559.2011.03937.x
  29. Takahashi K. Diagnosis of an extremely rare pleomorphic adenoma of the breast with core needle biopsy: A case report. Ann Med Surg (Lond) 2018;36:242–245. DOI: 10.1016/j.amsu.2018.10.037
  30. Leekha N, Muralee M, Mathews A, et al. Pleomorphic adenoma of breast-a case report and review of literature. Indian J Surg Oncol 2014;5(2):152–154. DOI: 10.1007/s13193-014-0310-y
  31. Moore M, Mills A, Dillon P, et al. Pleomorphic adenoma of the breast: a potential morphologic and molecular pitfall in the era of genomic risk stratification. Current problems in cancer; case reports 2021;3. DOI: 10.1016/j.cpccr.2020.100047
  32. Hayes MM, Lesack D, Girardet C, et al. Carcinoma ex-pleomorphic adenoma of the breast. Report of three cases suggesting a relationship to metaplastic carcinoma of matrix-producing type. Virchows Arch 2005;446(2):142–149. DOI: 10.1007/s00428-004-1137-7
  33. Seethala RR, Stenman G. Update from the 4th edition of the World Health Organization classification of Head and Neck tumours: tumors of the salivary gland. Head and Neck Pathol 2017;11(1):55–67. DOI: 10.1007/s12105-017-0795-0
  34. Bishop JA, Gagan J, Baumhoer D, et al. Sclerosing polycystic “adenosis” of salivary glands: a neoplasm characterized by pi3k pathway alterations more correctly named sclerosing polycystic adenoma. Head Neck Pathol 2020;14(3):630–636. DOI: 10.1007/s12105-019-01088-0
  35. Rico V, Shibahara Y, Monteiro M, et al. Salivary gland-type mammary carcinoma arising in microglandular adenosis: A case report and clinicopathological review of the literature. Cancer Treat Res Commun 24:100178. DOI: 10.1016/j.ctarc.2020.100178
  36. Murase R, Sumida T, Ishikawa A, et al. Novel therapeutic strategies for malignant salivary gland tumors: lessons learned from breast cancer. Int J Otolaryngol 2011;2011:187623. DOI: 10.1155/2011/187623
  37. Gibbons MD, Manne U, Carroll WR, et al. Molecular differences in mucoepidermoid carcinoma and adenoid cystic carcinoma of the major salivary glands. Laryngoscope 2001;111(8):1373–1378. DOI: 10.1097/00005537-200108000-00011
  38. Weed DT, Gomez-Fernandez C, Pacheco J, et al. MUC4 and ERBB2 expression in major and minor salivary gland mucoepidermoid carcinoma. Head Neck 2004;26(4):353–364. DOI: 10.1002/hed.10387
  39. Glisson B, Colevas AD, Haddad R, et al. Her2 expression in salivary gland carcinomas: dependence on histological subtype. Clin Cancer Res 2004;10(3):944–946. DOI: 10.1158/1078-0432.CCR-03-0253
  40. Shang J, Shui Y, Sheng L, et al. Epidermal growth factor receptor and human epidermal growth receptor 2 expression in parotid mucoepidermoid carcinoma: possible implications for targeted therapy. Oncol Rep 2008;19(2):435–440. DOI: 10.3892/or.19.2.435
  41. Clauditz TS, Reiff M, Gravert L, et al. Human epidermal growth factor receptor 2(HER2) in salivary gland carcinomas. Pathology 2011;43(5):459–464. DOI: 10.1097/PAT.0b013e3283484a60
  42. Ettl T, Stiegler C, Zeitler K, et al. EGFR, HER2, survivin, and loss of pSTAT3 characterize high-grade malignancy in salivary gland cancer with impact on prognosis. Hum Pathol 2012;43(6):921–931. DOI: 10.1016/j.humpath.2011.08.006
  43. Nakano T, Yamamoto H, Hashimoto K, et al. HER2 and EGFR gene copy number alterations are predominant in high-grade salivary mucoepidermoid carcinoma irrespective of MAML2 fusion status. Histopathology 2013;63(3):378–392. DOI: 10.1111/his.12183
  44. Lemound J, Schenk M, Keller G, et al. Cytogenetic and immunohistochemical biomarker profiling of therapy-relevant factors in salivary gland carcinomas. J Oral Pathol Med 2016;45(9):655–663. DOI: 10.1111/jop.12429
  45. Hashimoto K, Hayashi R, Mukaigawa T, et al. Concomitant expression of Ezrin and HER2 predicts distant metastasis and poor prognosis of patients with salivary gland carcinomas. Hum Pathol 2017;63:110–119. DOI: 10.1016/j.humpath.2017.02.017
  46. Szewczyk M, Marszałek A, Sygut J, et al. Prognostic markers in salivary gland cancer and their impact on survival. Head Neck 2019;41(9):3338–3347. DOI: 10.1002/hed.25857
  47. Hsieh MS, Lee YH, Jin YT, et al. Clinicopathological study of intraductal carcinoma of the salivary gland, with emphasis on the apocrine type. Virchows Arch 2020;477(4):581–592. DOI: 10.1007/s00428-020-02823-7
  48. Pires FR, da Cruz Perez DE, de Almeida OP, et al. Estrogen receptor expression in salivary gland mucoepidermoid carcinoma and adenoid cystic carcinoma. Pathol Oncol Res 2004;10(3):166–168. DOI: 10.1007/BF03033746
  49. Foschini MP, Krausz T. Salivary gland-type tumors of the breast: a spectrum of benign and malignant tumors including ”triple negative carcinomas” of low malignant potential. Semin Diagn Pathol 2010;27(1):77–90. DOI: 10.1053/j.semdp.2009.12.007
  50. Dori S, Trougouboff P, David R, et al. Immunohistochemical evaluation of estrogen and progesterone receptors in adenoid cystic carcinoma of salivary gland origin. Oral Oncol 2000;36(5):450–453. DOI: 10.1016/s1368-8375(00)00029-4
  51. Dori S, Vered M, David R, et al. HER2/Neu expression in adenoid cystic carcinoma of salivary gland origin: an immunohistochemical study. J Oral Pathol Med 2002;31(8):463–467. DOI: 10.1034/j.1600-0714.2002.00017.x
  52. Barrera JE, Shroyer KR, Said S, et al. Estrogen and progesterone receptor and p53 gene expression in adenoid cystic cancer. Head Neck Pathol 2008;2(1):13–18. DOI: 10.1007/s12105-007-0032-3
  53. Riad S et al. Expression of sex steroid hormone in adenoid cystic carcinoma of salivary gland origin. Alex Dent J 2009;34(1–3):37–44.
  54. Luo SD, Su YC, Chuang HC, et al. Estrogen receptor overexpression in malignant minor salivary gland tumors of sinonasal tract. Otolaryngol Head Neck Surg 2009;141(1):108–103. DOI: 10.1016/j.otohns.2009.03.003
  55. Khan AJ, DiGiovanna MP, Ross DA, et al. Adenoid cystic carcinoma: a retrospective clinical review. Int J Cancer 2001;96(3):149–158. DOI: 10.1002/ijc.1013
  56. Press MF, Pike MC, Hung G, et al. Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis. Cancer Res 1994 54(21):5675–5682.
  57. Shadaba A, Gaze MN, Grant HR, et al. The response of adenoid cystic carcinoma to tamoxifen. J Laryngol Otol 1997;111(12):1186–1189. DOI: 10.1017/s0022215100139684
  58. Yeoh CC, Dabab N, Rigby E, et al. Androgen receptor in salivary gland carcinoma: A review of an old marker as a possible new target. J Oral Pathol Med 2018;47(7):691–695. DOI: 10.1111/jop.12741
  59. Egebjerg K, Harwood CD, Woller NC, et al. HER2 positivity in histological subtypes of salivary gland carcinoma: A systemic review and metaanalysis. Front Oncol 2001;11:693394. DOI: 10.3389/fonc.2021.693394
  60. Fan CY, Wang J, Barnes EL, et al. Expression of androgen receptor ans prostatic specific markers in salivary duct carcinoma: an immunohistochemicalanalysis of 13 cases and review of the literature. Am J Surg Pathol 2000;24(4):579–586. DOI: 10.1097/00000478-200004000-00014
  61. Fan CY, Melhem MF, Hosal HS, et al. Expression of androgen receptor epidermal growth factor receptor, and transforming growth factor receptor alpha in salivary duct carcinoma. Arch Otolaryngol Head Neck Surg 2001;127(9):1075–1079. DOI: 10.1001/archotol.127.9.1075
  62. Skaálovaá A, Staárek I, Kuerovaá V, et al. Salivary duct carcinoma - a highly aggressive salivary gland tumor with her-2/neu oncoprotein overexpression. Pathol Res Pract 2001;197(9):621–626. DOI: 10.1078/03440338-00136
  63. Skálová A, Stárek I, Vanecek T, et al. Expression of HER-2/neu gene and protein in salivary duct carcinomas of parotid gland as revealed by fluorescence in-situ hybridization and immunohistochemistry. Histopathology 2003;42(4):348–356. DOI: 10.1046/j.1365-2559.2003.01600.x
  64. Jaehne M, Roeser K, Jaekel T, et al. Clinical and immunohistologic typing of salivary duct carcinoma: a report of 50 cases. Cancer 2005;103(12):2526–2533. DOI: 10.1002/cncr.21116
  65. Williams MD, Roberts D, Blumenschein GR Jr, et al. Differential expression of hormonal and growth factor receptors in salivary duct carcinomas: biologic significance and potential role in therapeutic stratification of patients. Am J Surg Pathol 2007;31(11):1645–1652. DOI: 10.1097/PAS.0b013e3180caa099
  66. Cornolti G, Ungari M, Morassi ML, et al. Amplification and overexpression of HER2/neu gene and HER2/neu protein in salivary duct carcinoma of the parotid gland. Arch Otolaryngol Head Neck Surg 2007;133(10):1031–1036. DOI: 10.1001/archotol.133.10.1031
  67. Nabili V, Tan JW, Bhuta S, et al. Salivary duct carcinoma: a clinical and histologic review with implications for trastuzumab therapy. Head Neck 2007;29(10):907–912. DOI: 10.1002/hed.20614
  68. Sygut D, Bień S, Ziółkowska M, et al. Immunohistochemical expression of androgen receptor in salivary gland cancers. Pol J Pathol 2008;59(4):205–210.
  69. Ettl T, Schwarz S, Kleinsasser N, et al. Overexpression of EGFR and absence of C-KIT expression correlate with poor prognosis in salivary gland carcinomas. Histopathology 2008;53(5):567–577. DOI: 10.1111/j.1365-2559.2008.03159.x
  70. Locati LD, Perrone F, Losa M, et al. Treatment relevant target immunophenotyping of 139 salivary gland carcinomas (SGCS). Oral Oncol 2009;45(11):986–990. DOI: 10.1016/j.oraloncology.2009.05.635.
  71. Di Palma S, Simpson RH, Marchiò C, et al. Salivary duct carcinomas can be classified into luminal androgen receptor-positive, HER2 and basal-like phenotypes. Histopathology 2012;61(4):629–643. DOI: 10.1111/j.1365-2559.2012.04252.x
  72. Suzuki S, Dobashi Y, Minato H, et al. EGFR and HER2-Akt-mTOR signaling pathways are activated in subgroups of salivary gland carcinomas. Virchows Arch 2012;461(3):271–282. DOI: 10.1007/s00428-012-1282-3
  73. Cros J, Sbidian E, Hans S, et al. Expression and mutational status of treatment-relevant targets and key oncogenes in 123 malignant salivary gland tumours. Ann Oncol 2013;24(10):2624–2629. DOI: 10.1093/annonc/mdt338
  74. Nardi V, Sadow PM, Juric D, et al. Detection of novel actionable genetic changes in salivary duct carcinoma helps direct patient treatment. Clin Cancer Res 2013;19(2):480–490. DOI: 10.1158/1078-0432.CCR-12-1842
  75. Kondo Y, Kikuchi T, Esteban JC, et al. Intratumoral heterogeneity of HER2 protein and amplification of HER2 gene in salivary duct carcinoma. Pathol Int 2014;64(9):453–459. DOI: 10.1111/pin.12195
  76. Masubuchi T, Tada Y, Maruya S, et al. Clinicopathological significance of androgen receptor, HER2, Ki-67 and EGFR expressions in salivary duct carcinoma. Int J Clin Oncol 2015;20(1):35–44. DOI: 10.1007/s10147-014-0674-6
  77. Han MW, Roh JL, Choi SH, et al. Prognostic factor and outcome analysis of salivary duct carcinoma. Auris Nasus Larynx 2015;42(6):472–477. DOI: 10.1016/j.anl.2015.04.005
  78. Luk PP, Weston JD, Yu B, et al. Salivary duct carcinoma: Clinicopathologic features, morphologic spectrum, and somatic mutations. Head Neck 2016;38 Suppl 1:E1838–E1847. DOI: 10.1002/hed.24332
  79. Kusafuka K, Kawasaki T, Maeda M, et al. Salivary duct carcinoma with rhabdoid features: a salivary counterpart of pleomorphic lobular carcinoma of the breast. Histopathology 2017;70(2):164–173. DOI: 10.1111/his.12987
  80. Takase S, Kano S, Tada Y, et al. Biomarker immunoprofile in salivary duct carcinomas: clinicopathological and prognostic implications with evaluation of the revised classification. Oncotarget 2017;8(35):59023–59035. DOI: 10.18632/oncotarget.19812
  81. Khoo TK, Yu B, Smith JA, et al. Somatic mutations in salivary duct carcinoma and potential therapeutic targets. Oncotarget 2017;8(44):75893–75903. DOI: 10.18632/oncotarget.18173
  82. Boon E, Bel M, van Boxtel W, et al. A clinicopathological study and prognostic factor analysis of 177 salivary duct carcinoma patients from The Netherlands. Int J Cancer 2018;143(4):758–766. DOI: 10.1002/ijc.31353
  83. Beck ACC, Lohuis PJFM, Al-Mamgani A, et al. Salivary duct carcinoma: evaluation of treatment and outcome in a tertiary referral institute. Eur Arch Otorhinolaryngol 2018;275(7):1885–1892. DOI: 10.1007/s00405-018-5000-x
  84. Ryu HJ, Koh YW, Yoon SO. The implications of TrkA and MET aberrations in novo salivary duct carcinoma. Hum Pathol 2018;81:18–25. DOI: 10.1016/j.humpath.2018.04.027
  85. Kanazawa T, Misawa K, Fukushima H, et al. Epigenetic inactivation of galanin receptors in salivary duct carcinoma of the parotid gland: potential utility as biomarkers for prognosis. Oncol Lett 2018;15(6):9043–9050. DOI: 10.3892/ol.2018.8525
  86. Liang L, Williams MD, Bell D. Expression of PTEN, androgen receptor, HER2/neu, cytokeratin 5/6, estrogen receptor-beta, HMGA2, and PLAG1 in salivary duct carcinoma. Head Neck Pathol 2019;13(4):529–534. DOI: 10.1007/s12105-018-0984-5
  87. Santana T, Pavel A, Martinek P, et al. Biomarker immunoprofile and molecular characteristics in salivary duct carcinoma: clinicopathological and prognostic implications. Hum Pathol 2019;93:37–47. DOI: 10.1016/j.humpath.2019.08.009
  88. Villepelet A, Lefèvre M, Verillaud B, et al. Salivary duct carcinoma: prospective multicenter study of 61 cases of the Réseau d’Expertise Français des Cancers ORL rares. Head Neck 2018;41(3):584–591. DOI: 10.1002/hed.25194
  89. Gargano SM, Senarathne W, Feldman R, et al. Novel therapeutic targets in salivary duct carcinoma uncovered by comprehensive molecular profiling. Cancer Med 2019;8(17):7322–7329. DOI: 10.1002/cam4.2602
  90. Chatzopoulos K, Collins AR, Sotiriou S, et al. Increased ERBB2 gene copy numbers reveal a subset of salivary duct carcinomas with high densities of tumor infiltrating lymphocytes and PD-L1 expression. Head Neck Pathol 2020;14(4):951–965. DOI: 10.1007/s12105-020-01163-x
  91. Skálová A, Vanecek T, Sima R, et al. Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity. Am J Surg Pathol 2010;34(5):599–608. DOI: 10.1097/PAS.0b013e3181d9efcc
  92. Rooper LM. Emerging entities in salivary pathology: a practical review of sclerosing microcystic adenocarcinoma, microsecretory adenocarcinoma, and secretory myoepithelial carcinoma. Surg Pathol Clin 2021;14(1):137–150. DOI: 10.1016/j.path.2020.10.003
  93. Pia-Foschini M, Reis-Filho JS, Eusebi V, et al. Salivary gland-like tumours of the breast: surgical and molecular pathology. J Clin Pathol 2003;56(7):497–506. DOI: 10.1136/jcp.56.7.497
  94. Flynn C, Kadivar M, Kwon MY, et al. Basal cell adenocarcinoma arising in salivary gland metaplasia of the breast: a novel salivary gland-type tumor developing in the breast. Hum Pathol 2012;43(10):1764–1771. DOI: 10.1016/j.humpath.2012.02.013
  95. Walls AL, Middleton LP, El-Naggar AK, et al. Basaloid salivary gland-analogue tumors of the mammary gland: clinicopathologic assessment of a rare subtype. Int J Pathol Clin Res 2016;2(3). DOI: 10.23937/2469-5807/1510042
  96. Shin SJ, Rosen PP. Solid variant of mammary adenoid cystic carcinoma with basaloid features: a study of nine cases. Am J Surg Pathol 2002;26(4):413–420. DOI: 10.1097/00000478-200204000-00002
  97. Lamovec J, Falconieri G, Salviato T, et al. Basaloid carcinoma of the breast: a review of 9 cases, with delineation of a possible clinicopathologic entity. Ann Diagn Pathol 2017;187(10):2139–2151. DOI: 10.1016/j.anndiagpath.2007.01.009
  98. Geyer CF, Pareja F, Weigelt B, et al. The spectrum of triple-negative breast disease: High- and low-grade lesions. Am J Pathol 2017;187(10):2139–2151. DOI: 10.1016/j.ajpath.2017.03.016
  99. Seethala. Salivary Gland Tumors: Current Concepts and Controversies. Surg Pathol Clin 2017;10(1):155–176. DOI: 10.1016/j.path.2016.11.004
  100. Giordano G, Gabrielli M, Gnetti L, et al. Oncocytic carcinoma of parotid gland: a case report with clinical, immunohistochemical and ultrastructural features. World J Surg Oncol 2006;4:54. DOI:10.1186/1477-7819-4-54
  101. Oh DY, Bang YJ. HER2-targeted therapies - a role beyond breast cancer. Nat Rev Clin Oncol 2020;17(1):33–48. DOI: 10.1038/s41571-019-0268-3
  102. Geiger JL, Ismaila N, Beadle B, et al. Management of salivary gland malignancy: ASCO guideline. J Clin Oncol 2021;39(17):1909–1941. DOI: 10.1200/JCO.21.00449
  103. Kurzrock R, Bowles DW, Kang H, et al. Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study. Ann Oncol 2020;31(3):412–421. DOI: 10.1016/j.annonc.2019.11.018
  104. Jhaveri KL, Wang XV, Makker V, et al. Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q. Ann Oncol 2021;30(11):1821–1830. DOI: 10.1093/annonc/mdz291
  105. Fushimi C, Tada Y, Takahashi H, et al. A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma. Ann Oncol 2018;29(4):979–984. DOI: 10.1093/annonc/mdx771
  106. Boon E, van Boxtel W, Buter J, et al. Androgen deprivation therapy for androgen receptor-positive advanced salivary duct carcinoma: a nationwide case series of 35 patients in The Netherlands. Head Neck 2018;40(3):605–613. DOI: 10.1002/hed.25035
  107. Viscuse PV, Price KA, Garcia JJ, et al. First line androgen deprivation therapy vs. chemotherapy for patients with androgen receptor positive recurrent or metastatic salivary gland carcinoma—a retrospective study. Front Oncol 2019;9:701. DOI: 10.3389/fonc.2019.00701
  108. Locati LD, Perrone F, Cortelazzi B, et al. Clinical activity of androgen deprivation therapy in patients with metastatic/relapsed androgen receptor-positive salivary gland cancers. Head Neck 2016;38(5):724–731. DOI: 10.1002/hed.23940
  109. Ho AL, Foster NR, Zoroufy AJ, et al. Phase II study of Enzalutamide for patients with androgen receptor-positive salivary gland cancers (Alliance A091404). J Clin Oncol 2022;40(36):4240–4249. DOI: 10.1200/JCO.22.00229
  110. Omar TA, ElDidi F, Nawar WM, et al. A potential role of sex hormone receptor anagonists in the treatment of malignant salivary gland tumors, as compared to breast cancer: a review of literature. Tanta Dental Journal 2013;10(2):75–85.DOI: 10.1016/j.tdj.2013.08.006
  111. Elkin AD, Jacobs CD. Tamoxifen for salivary gland adenoid cystic carcinoma: report of two cases. J Cancer Res Clin Oncol 2008;134(10):1151–1153. DOI: 10.1007/s00432-008-0377-3
  112. Campos-Gómez S, Flores-Arredondo JH, Dorantes-Heredia R, et al. Case report: anti-hormonal therapy in the treatment of ductal carcinoma of the parotid gland. BMC Cancer 2014;14:701. DOI: 10.1186/1471-2407-14-701
  113. Yoshimura T, Sumida T, Liu S, et al. Growth inhibition of human salivary gland tumor cells by introduction of progesterone (Pg) receptor and Pg treatment. Endocr Relat Cancer 2007;14(4):1107–1116. DOI: 10.1677/erc.1.01253
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.